In fact, a recent study investigating lymph nodes in patients receiving CD19 CAR-T therapy revealed a remarkable complete depletion of B cells in 6 SLE and 2 SSc patients, a level unattainable with monoclonal antibodies like rituximab (53). This evidence concerns the gene CD19 and systemic sclerosis.